Abstract
Not only local parameters but also genetic determinants like the HLA genes may play a role in the development and clinical behavior of malignant tumors. In skin melanoma the presence of HLA-B40 is associated with a poor prognosis. We tested the hypothesis that the clinical behavior of uveal melanoma is influenced by the HLA type of the patient. The HLA types of 44 patients with uveal melanoma had been determined before operation with a view to using the cornea of the enucleated eye for an HLA-matched corneal transplantation. We compared the ABO and HLA types of the patients with the development of metastases and with the ten-year patient survival. An association was observed between the presence of HLA-B40 and death due to metastasis of uveal melanoma. We conclude that the HLA type of the patient may influence the clinical behavior not only of skin melanoma but also of uveal melanoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lamm LU, Kissmeyer-Nielsen F, Kjerbye KE, Mogensen B, Petersen NC. HL-A and ABO antigens and malignant melanoma. Cancer 1974; 33: 1458–61.
Cavalier B, Daveau M, Gilbert D, Fontaine M, Cesarini JP, Delpech B. Augmentation de l'antigene HLA-A9 dans les melanomes malins, principalement dans les formes metastatiques ou les recidives. A propos de 105 melanomes dont 34 formes graves. CR Acad Sci Paris 1980; 291: 241–43.
Pellegris G, Illeni, MT, Vaglini M, Rovini D, Cascinelli N, Masserine C. HLA antigens in malignant melanoma patients. Tumori 1980; 66: 51–58.
Pollack MS, Livingstone PO. HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosis. Tissue Antigens 1985; 26: 262.
Bertrams J, Spitznas M, Rommelfanger M. Missing evidence for HLA antigen association with Eales' disease, chorioretinitis, central serous retinopathy and malignant choroidal melanoma. Invest Ophthalmol 1978; 17: 918–20.
Dieckhues B, Jümann G, Küchle HJ, Püttmann T. HLA Antigene bei Augenerkrankungen. Klin Mbl Augenheilk 1979; 175: 681–85.
Völker-Dieben HJ, D'Amaro J, Lange P de, Wolff-Rouendaal D de. HLA and ABO antigens in patients with malignant choroidal melanoma. Clin Exp Immunol 1983; 53: 581–88.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. J Cancer 1976/1977; 34; 585–612; 35: 1–39.
Oosterhuis JA, Went LN, Lynch HT. Primary choroidal and cutaneous melanomas, bilateral choroidal melanomas, and familial occurrence of melanomas. Br J Ophthalmol 1982; 66: 230.
Vink J, Crijns MW, Bergman W, Oosterhuis JA, Went LN. Ocular melanoma in families with dysplastic nevus syndrome (DNS). J Am Acad Dermatol 1990; 23: 858–62.
Demenais FM. HLA and malignant melanoma. In: Lynch HT, Fusaro RM, eds. Hereditary malignant melanoma. Boca Raton: CRC Press, 1991: 75–86.
Lagaay AM, D'Amaro, J, Ligthart GJ, Schreuder GMTh, Rood JJ van, Hijmans W. Longevity and heredity in humans: Association with the human leucocyte antigen phenotype. In: Pierpaoli W, Fabris N, eds. Physiological senescence and its postponement: theoretical approaches and rational interventions. Ann New York Acad Sci, 1991; 621: 78–89.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jager, M.J., Völker-Dieben, H.J., De Wolff-Rouendaal, D. et al. Possible relation between HLA and ABO type and prognosis of uveal melanoma. Doc Ophthalmol 82, 43–47 (1992). https://doi.org/10.1007/BF00156992
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00156992